Department of Hematology and Oncology, Campus Benjamin Franklin, Charité, University Hospital Berlin, Berlin, Germany.
Blood. 2013 Jun 6;121(23):4749-52. doi: 10.1182/blood-2012-11-465138. Epub 2013 Apr 19.
Early T-cell precursor (ETP) acute lymphoblastic leukemia (ALL) is a high-risk subgroup of T-lineage ALL characterized by specific stem cell and myeloid features. In adult ETP-ALL, no comprehensive studies on the genetic background have been performed to elucidate molecular lesions of this distinct subgroup. We performed whole-exome sequencing of 5 paired ETP-ALL samples. In addition to mutations in genes known to be involved in leukemogenesis (ETV6, NOTCH1, JAK1, and NF1), we identified novel recurrent mutations in FAT1 (25%), FAT3 (20%), DNM2 (35%), and genes associated with epigenetic regulation (MLL2, BMI1, and DNMT3A). Importantly, we verified the high rate of DNMT3A mutations (16%) in a larger cohort of adult patients with ETP-ALL (10/68). Mutations in epigenetic regulators support clinical trials, including epigenetic-orientated therapies, for this high-risk subgroup. Interestingly, more than 60% of adult patients with ETP-ALL harbor at least a single genetic lesion in DNMT3A, FLT3, or NOTCH1 that may allow use of targeted therapies.
早期 T 细胞前体(ETP)急性淋巴细胞白血病(ALL)是 T 系 ALL 的一种高危亚组,其特征是具有特定的干细胞和髓样特征。在成人 ETP-ALL 中,尚未进行全面的遗传背景研究以阐明这一独特亚组的分子病变。我们对 5 对 ETP-ALL 样本进行了全外显子组测序。除了已知参与白血病发生的基因(ETV6、NOTCH1、JAK1 和 NF1)中的突变外,我们还在 FAT1(25%)、FAT3(20%)、DNM2(35%)和与表观遗传调控相关的基因(MLL2、BMI1 和 DNMT3A)中发现了新的高频突变。重要的是,我们在更大的成人 ETP-ALL 患者队列(10/68)中验证了 DNMT3A 突变的高发生率(16%)。表观遗传调节剂的突变支持针对这一高危亚组的临床试验,包括表观遗传定向治疗。有趣的是,超过 60%的成人 ETP-ALL 患者至少存在 DNMT3A、FLT3 或 NOTCH1 中的单个遗传病变,这可能允许使用靶向治疗。